New Hydrogen Treatment Protects Brain After Stroke in Animal Study
Constructing Mg-Based Hydrogen Container for Mitochondrial Dysfunction and Neuronal Ferroptosis in TCAR-Induced Cerebral Ischemia/Reperfusion Injury
Research hubs: Brain & Nervous System · Cardiovascular System
This research was done in animals. Results in animals often don't carry over to people.
- Evidence type
- Animal study (rat)
- Authors
- Weijian Fan, Qingqing Guan, Zhiheng Xu, Lanmei Lin, Juan Du, Bo Yu, Wenjiang Ding, Haiyan Yang, Jia Pei, Jinyun Tan
- Journal
- Advanced Healthcare Materials
- Year
- 2025
- PMID
- 41457679
- Study Type
- Rat
- Delivery
- Gas (Sustained Release)
- Dose
- intraperitoneal injection of magnesium hydride microparticles (MgH2)
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 1 (OpenAlex, as of November 2026)
- Country
- China
TL;DR
Magnesium hydride microparticles delivered hydrogen to the brain, reducing oxidative stress and protecting neurons by improving mitochondrial function after ischemia-reperfusion injury.
Key Finding
Magnesium hydride microparticles successfully delivered sustained, high-dose hydrogen to the brain and reduced reactive oxygen species while protecting brain cells from ferroptosis and restoring mitochondrial function in a rabbit model of cerebral ischemia/reperfusion injury.
Summary
This study tested a new way to deliver hydrogen gas to the brain using magnesium hydride microparticles (tiny particles that slowly release hydrogen) in rabbits with a type of brain injury caused by temporarily blocking blood flow to the brain. The researchers found that this hydrogen delivery method reduced harmful molecules called reactive oxygen species, protected brain cells from a type of damage called ferroptosis, and restored normal function to mitochondria (the energy-producing parts of cells).
Practical Takeaway
This is early-stage research in animals only, not humans. While the results suggest that sustained hydrogen delivery to the brain may have neuroprotective effects in stroke-like injuries, much more research—including human trials—would be needed before this approach could be considered for treating stroke or brain injury in people. The delivery method itself is novel and addresses previous challenges in getting hydrogen across the blood-brain barrier, but safety and effectiveness in humans remain unknown.
Abstract (excerpt)
ABSTRACT Mitochondrial dysfunction and reactive oxygen species (ROS) overexpression are crucial factors inducing neuronal ferroptosis in cerebral ischemia/reperfusion injury (CIRI). Some therapeutics like RNAs and anti‐oxidation drugs have been developed to regulate the functions of mitochondria…